To Gain More Insights into the Hemoglobinopathy Treatment Drugs Market, Browse Summary of the Research Report –
Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. Hemoglobin is present in the red blood cells that transport oxygen from the lungs to the body. Hemoglobinopathy disorder is inherited and are passed on from one generation to another. It is further classified into two categories – thalassemia syndrome and structural hemoglobin variants. Thalassemia syndrome includes disorder related to synthesis defect. The synthesis defect of alpha globin gives rise to alpha thalassemia and defect in beta globin give rise to beta thalassemia. The structural hemoglobin variants occur due to alteration of alpha and beta chains that cause defect in structure.
https://www.coherentmarketinsights.com/market-insight/hemoglobinopathy-treatment-drugs-market-4059
Hemoglobinopathy is a group of hereditary blood disorders involving an abnormality in the structure of hemoglobin. These disorders include both sickle cell disease (SCD) and thalassemia. Common symptoms of the condition include severe pain, shortness of breath, enlarged spleen, and growth problems in children. Other types of hemoglobinopathies linked to the structural hemoglobin variants are HbS, HbE, and HbC. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Drugs to treat the symptoms of hemoglobinopathy include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. According to the data of National Center for Biotechnology Information, more than 90% of patients currently survive the adulthood. Optimally treated patients have a projected life span of 50 to 60 years.
Increasing incidence and prevalence of sickle cell disease (SCD) is expected to propel growth of the global hemoglobinopathy treatment drugs market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in October 2019, SCD affects around 100,000 Americans every year. Moreover, as per the same source, around 1 in 13 African-American babies are born with sickle cell trait (SCT).
However, failing clinical trials for the treatment of sickle cell anemia are expected to hinder the market growth. For instance, in August 2019, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints. Moreover, high costs, and difficulties associated with diagnosis of hemoglobinopathies such as lack of proper knowledge and lack of skilled professionals are expected to restrain growth of the market up to certain extent.
“We Do Offer Sample of Hemoglobinopathy Treatment Drugs Market Report. Kindly go through the follow information in order to access sample copy.”
https://www.coherentmarketinsights.com/insight/request-sample/4059
Table of Contents
1. Research Objectives and Assumptions
◦ Research Objectives
◦ Assumptions
◦ Abbreviations
2. Market Purview
◦ Report Description
▪ Market Definition and Scope
◦ Executive Summary
▪ Market Snippet, By Drug Type
▪ Market Snippet, By Distribution Channel
▪ Market Snippet, By Region
◦ Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
◦ Market Dynamics
▪ Drivers
▪ Restraints
▪ Market Opportunities
◦ Impact Analysis
◦ Market Trends
◦ Regulatory Scenario
◦ Reimbursement Scenario
◦ Epidemiology
◦ PEST Analysis
◦ Recent Product Launch
◦ Merger and Acquisition Scenario
Top players in the market
Key players operating in the hemoglobinopathy treatment drugs market include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Prolong Pharmaceuticals, Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
Research methodology adopted by Coherent Market Insights
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
• Primary Research (Trade Surveys and Experts Interviews)
• Desk Research
• Proprietor Data Analytics Model
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Request A Sample Copy Hemoglobinopathy Treatment Drugs Market Report Click here:
https://www.coherentmarketinsights.com/insight/request-sample/4059
Get PDF Research Report Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/4059
Buy Now this Premium Report to Grow your Business @
https://www.coherentmarketinsights.com/insight/buy-now/4059
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
Contact Us:
Name: Mr. Raj Shah
Email: [email protected]
Phone: US +12067016702
Country: United States
Visit our Blog: https://hospitalhealthcareblog.wordpress.com/